A number of studies suggest that prostate cancer patients with germline BRCA1 or BRCA2 mutations present at a younger age, have more poorly differentiated tumors and present with a more aggressive clinical course of disease2, 5–7. The gene discussed is BRCA2; the disease is Familial prostate cancer.